Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoprotein disorders and cardiovascular risk.

J Genest1

  • 1Cardiovascular Genetics Laboratory, McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada. jacques.genest@muhc.mcgill.ca

Journal of Inherited Metabolic Disease
|August 2, 2003
PubMed
Summary

Genetic factors significantly contribute to lipoprotein disorders, increasing risks for cardiovascular disease and pancreatitis. This review highlights monogenic causes and novel high-density lipoprotein issues, emphasizing early screening and treatment, especially in children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina.

American heart journal·1998
Same author

Plasma triglyceride-rich lipoprotein and high density lipoproteins disorders associated with atherosclerosis.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·1998
Same author

Genetics of lipoprotein disorders.

Endocrinology and metabolism clinics of North America·1998
Same author

Angiotensin converting enzyme insertion/deletion polymorphism in French Canadian subjects with premature coronary artery disease.

Pathologie-biologie·1998
Same author

Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB.

European journal of clinical investigation·1998
Same author

Lipoprotein lipase gene mutations in coronary artery disease.

The Canadian journal of cardiology·1998

Area of Science:

  • Lipid metabolism and cardiovascular genetics
  • Human genetics and disease etiology
  • Atherosclerosis and lipoprotein research

Background:

  • Dyslipoproteinaemia, characterized by abnormal lipoprotein levels, is a major contributor to human diseases, primarily atherosclerotic vascular disease.
  • Key risk factors include elevated low-density lipoprotein cholesterol (LDL-C), very low-density lipoproteins (VLDL), lipoprotein(a), and reduced high-density lipoproteins (HDL-C), alongside severe hypertriglyceridemia.
  • Lifestyle and genetic factors interplay in the development of these disorders, which often remain asymptomatic until critical organ damage occurs.

Purpose of the Study:

  • To review the significant role of genetic lipoprotein disorders in human disease.
  • To focus on monogenic causes linked to coronary artery disease and new insights into high-density lipoprotein disorders.
  • To discuss the implications for screening and treatment strategies, particularly for pediatric populations.

Related Experiment Videos

Main Methods:

  • Literature review focusing on genetic aetiologies of dyslipoproteinaemia.
  • Analysis of monogenic disorders associated with coronary artery disease.
  • Examination of novel genetic causes for high-density lipoprotein disorders.

Main Results:

  • Genetic factors are a primary driver for various dyslipoproteinaemias, impacting cardiovascular health.
  • Monogenic disorders represent a significant cause of premature coronary artery disease.
  • Emerging research identifies new genetic underpinnings for high-density lipoprotein abnormalities.

Conclusions:

  • Genetic lipoprotein disorders are crucial in human pathology, necessitating a thorough understanding for effective management.
  • Early identification and intervention, considering disease severity and long-term vascular risk, are vital, especially in children.
  • Further research into genetic causes and therapeutic benefits is essential for improving patient outcomes.